好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Alzheimer’s Pathology in Patients with and Without Motoric Cognitive Risk Syndrome: A Retrospective Study in Western Switzerland University Memory Clinics
Aging, Dementia, and Behavioral Neurology
P10 - Poster Session 10 (8:00 AM-9:00 AM)
13-009

To examine Alzheimer’s pathology through CSF biomarkers in memory clinic patients with and without Motoric Cognitive Risk (MCR) syndrome.

MCR, defined by subjective cognitive complaints and slow gait speed, is a clinical screening tool proposed to identify older adults at increased risk for dementia. However, the CSF biomarker profile of Alzheimer’s disease (AD) in memory clinic populations with and without MCR remains poorly characterized.

We retrospectively included 79 non-demented participants (mean age 71.4 ± 8.0 years; 38% female) from the Leenaards Memory Center (Lausanne University Hospital) and the Geneva Memory Center (Geneva University Hospital) who underwent both CSF analysis and gait assessment. CSF concentrations of amyloid-β42, phosphorylated tau, and total tau were obtained during routine lumbar puncture and A/T/N profiles were classified according to the NIA-AA research framework. Group comparisons used chi-square or Fisher’s exact tests, and multivariable logistic regression models examined associations between MCR status and CSF biomarkers, adjusting for age, sex, and education.

Thirty-nine participants (49%) met MCR criteria. MCR + and MCR - groups did not differ in age, sex, education, or global and domain-specific cognitive performance. Vascular risk factors and comorbidities were similar, although depressive symptoms were more frequent among MCR+ individuals (RR = 2.11; 95% CI 1.39 to 3.19; p < .001). A/T profiles and the proportions of biomarker-positive individuals did not differ significantly between groups. CSF biomarkers were not independently associated with MCR status in multivariable models.

In memory clinic populations, MCR is frequent among non-demented patients and CSF biomarker profiles are comparable between individuals with and without MCR. These findings suggest that MCR represents a biologically heterogenous clinical syndrome encompassing both AD and non-AD pathologies and underscore the importance of biomarker-based characterization to refine diagnostic assessment in clinical practice.

Authors/Disclosures
Hadrien Lalive
PRESENTER
Mr. Lalive has nothing to disclose.
Eline Poinsignon-Clavel Miss Poinsignon-Clavel has nothing to disclose.
Federica Ribaldi, PhD Dr. Ribaldi has nothing to disclose.
Giovanni B. Frisoni Dr. Frisoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Frisoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Frisoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk. The institution of Dr. Frisoni has received research support from Novo Nordisk.
Giulia Bommarito The institution of Dr. Bommarito has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai.
Gilles Allali, MD, PhD Dr. Allali has nothing to disclose.